cas 2448173-19-9|| where to buy 4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

Nom du produit:4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

IUPAC Name:4-{6-iodo-7H-pyrrolo[2,3-d]pyrimidin-4-yl}morpholine

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2448173-19-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:2448173-19-9; Formule moléculaire:C10H11IN4O; Point de fusion:-; Code SMILES:IC1=CC2=C(N=CN=C2N1)N1CCOCC1; Densité:

: Numéro de catalogue:CM1045040; Poids moléculaire:330.13; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: BMF-219; Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.